Org

aniz

ed b

y IM

K In

stitu

te fo

r med

icin

e an

d co

mm

unic

atio

n Lt

d2nd Conferenceof the International MS Cognition Society

June 28-29, 2013University Hospital Zurich, Switzerlandwww.imk.ch/imscogs2013

Program

2

Zusa

mm

enfa

ssun

g Fa

chin

form

atio

n Be

tafe

ron.

Zusa

mm

ense

tzun

g: E

ine

Dur

chst

echf

lasc

he e

nthä

lt al

s W

irkst

off:

Inte

rfer

onum

bet

a-1b

AD

Nr

(8 M

io. I

U/m

l nac

h Re

kons

titut

ion)

Hilf

ssto

ffe:

Hum

anal

bum

in, M

anni

tol.

Indi

katio

nen:

Bei

Pat

ient

en m

it sc

hubf

örm

ig-r

emitt

iere

nder

Mul

tiple

r Sk

lero

se (

MS)

. Bei

sek

un-

där

chro

nisc

h-pr

ogre

dien

ter

MS

und

bei P

atie

nten

mit

eine

m e

rste

n kl

inisc

hen,

auf

MS

hinw

eise

nden

neu

rolo

gisc

hen

Erei

gnis.

Dos

ieru

ng/A

nwen

dung

: Erw

achs

ene

und

Kin

der

und

Juge

ndlic

he ü

ber

12 J

ahre

: 8 M

illio

nen

IU, a

ls In

jekt

ion

alle

zw

ei T

age

subk

utan

. K

ontr

aind

ikat

ione

n: Ü

bere

mpf

indl

ichk

eit

gege

n na

türli

ches

ode

r re

kom

bina

ntes

Int

erfe

ron

beta

ode

r H

uman

albu

min

; Sc

hwan

gers

chaf

t; sc

hwer

e de

pres

sive

Erkr

anku

ngen

und

/ode

r Su

izid

neig

ung

in d

er A

nam

nese

; Le

berin

suff

izie

nz;

nich

t ad

äqua

t ko

ntro

llier

te

Epile

psie

. Vor

sich

tsm

assn

ahm

en: V

orsic

ht b

ei P

atie

nten

mit

depr

essiv

en S

töru

ngen

ode

r K

ram

pfan

fälle

n in

Ana

mne

se; P

atie

nten

unt

er A

ntie

pile

ptik

a, m

it A

näm

ie, T

hrom

bozy

tope

nie,

Leu

kope

nie

oder

ges

tört

er S

child

drüs

enfu

nktio

n. V

or B

ehan

dlun

gsbe

ginn

und

in

rege

lmäs

sigen

Abs

tänd

en fo

lgen

de K

ontr

olle

n: v

ollst

ändi

ges B

lutb

ild, D

iffer

entia

lblu

tbild

, übl

iche

Lab

orw

erte

, GO

T, G

PT, G

amm

a-G

T. In

tera

ktio

nen:

Vor

sicht

bei

Ein

nahm

e vo

n Su

bsta

nzen

, der

en C

lear

ance

star

k vo

m Z

ytoc

hrom

-P45

0-Sy

stem

abh

ängt

. Sch

wan

gers

chaf

t/St

illze

it: F

raue

n im

geb

ärfä

hige

n A

lter s

ollte

n ge

eign

ete

Kon

traz

eptio

nsm

assn

ahm

en tr

effe

n. W

ähre

nd d

er S

tillz

eit e

ntw

eder

das

Stil

len

oder

die

Beh

andl

ung

mit

Beta

fero

n ab

brec

hen.

Une

rwün

scht

e W

irkun

gen:

Seh

r häu

fig: R

eakt

ione

n an

der

Inje

ktio

nsst

elle

, grip

pear

-tig

e Sy

mpt

ome.

Häu

fig: H

autn

ekro

sen.

Gel

egen

tlich

: Anä

mie

, Thr

ombo

zyto

peni

en, L

euko

peni

e, E

rhöh

unge

n de

r SG

OT-

, SG

PT-,

Gam

ma-

GT-

, Bili

rubi

n-, T

rigly

cerid

e-W

erte

; und

erh

öhte

r M

uske

ltonu

s, D

epre

ssio

n, a

rter

ielle

Hyp

erto

nie,

Übe

lkei

t, Er

brec

hen,

Haa

raus

fall,

U

rtik

aria

, Pru

ritus

, Exa

nthe

m u

nd M

yalg

ie. S

onst

ige

Hin

wei

se: L

ager

ung

unte

r 25°

C, n

icht

ein

frie

ren.

Hal

tbar

keit

des P

rodu

kts n

ach

Reko

nstit

utio

n bi

s zu

3 St

unde

n be

i 2-8

°C. V

erka

ufsk

ateg

orie

: B. W

eite

rfüh

rend

e In

form

atio

nen

entn

ehm

en S

ie b

itte

der F

achi

nfor

mat

ion

au

f w

ww

.swiss

med

icin

fo.c

h.

L.CH

.STH

.03.

2013

.011

7-D

E/FR

/IT1

Goo

din

et a

l. Su

rviv

al in

MS.

A r

ando

miz

ed c

ohor

t st

udy

21 y

ears

aft

er t

he s

tart

of

the

pivo

tal I

FNβ-

1b t

rial

. Neu

rolo

gy 2

012;

78:

131

5-13

22.

L.CH

.STH

.12.

2012

.009

1-D

E/FR

Bayer (Schweiz) AGGrubenstrasse 6, 8045 Zürich

Signifi kanter Überlebensvorteil Eine initiale Betaferon®-Behandlung resultiert in einer Risikoreduktion derMortalität um 47%, im Vergleich zur Placebo-Gruppe.1

Betaferon® – mit Familie in die Zukunft.

3

Contents

Welcome 5

General information 6

Accommodation 9

Travel information 10

Social program 12

Partner companies 13

Scientific program 14-21

Friday | 28.06.2013 14

Saturday | 29.06.2013 18

Adresses of invited speakers 23

Posters 25

Registration and hotel booking:

www.imk.ch/imscogs2013

2011-1

1-C

HE-

TYS

-109-d

Referenzen: 1. Kappos L et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431 – 441Gekürzte Fachinformation TYSABRI. Z: Eine Durchstechflasche enthält 300 mg/15 ml (20 mg/ml) Natalizumab. I: Monotherapie von schubförmig remittierend verlau-fender Multipler Sklerose bei Patienten mit hoher Krankheitsaktivität trotz Behandlung mit einem Interferon beta oder bei Patienten mit rasch fortschreitendem Verlauf. Bei Indikationsstellung bzw. vor Therapiebeginn das PML-Risiko berücksichtigen (siehe V). D: 300 mg alle 4 Wochen als intravenöse Infusion. Die Therapie mit TYSABRI muss von Spezialisten (Neurologen) in Zentren mit raschem Zugang zu MRI (Magnetresonanztomographie) eingeleitet und überwacht werden. Patienten sind in einem für TYSABRI vorgesehenen Monitoringprogramm aufzunehmen. KI: Überempfindlichkeit auf Natalizumab oder einen Hilfsstoff; Progressive Multifokale Leukoenzepha-lopathie (PML); erhöhtes Risiko für opportunistische Infektionen; Kombination mit Interferon beta oder Glatirameracetat; aktive Malignome; Personen unter 18 Jahren. V: Erhöhtes Risiko für die Entwicklung einer PML bei Vorliegen von folgenden unabhängigen Risikofaktoren: Vorhandensein von anti-JCV Antikörpern; immunsuppressive Behandlung vor der Therapie mit TYSABRI; Behandlungsdauer länger als 2 Jahre. Patienten mit allen drei Risikofaktoren tragen das höchste PML-Risiko. Für die Risiko-stratifizierung vor oder während der Behandlung sollte die Untersuchung auf anti-JCV-Antikörper erfolgen. Aufklärung des Patienten nach 2-jähriger Behandlungsdauer über das mit TYSABRI verbundene PML-Risiko notwendig; erhöhtes Risiko der Entwicklung eines IRIS (Immune Reconstitution Inflammatory Syndrome) bei Patienten mit PML; erhöhtes Risiko von opportunistischen Infektionen; Risiko von Überempfindlichkeitsreaktionen einschliesslich schwerer systemischer Reaktionen während oder kurz nach der Infusion; insbesondere bei den ersten Infusionen bzw. bei Anwendung nach kurzzeitiger Exposition und einer längeren Zeitdauer ohne Behandlung; nach einer früheren Behandlung mit Immunsuppressiva ausreichende Erholung des Immunstatus notwendig; Untersuchung auf Antikörper notwendig, falls Verschlechterung der Erkrankung oder infusionsbedingte Ereignisse. Vorsicht bei Beendigung der Therapie: pharmakodynamische Wirkung hält noch ca. 12 Wochen an. S: TYSABRI darf nicht in der Schwangerschaft verwendet werden, es sei denn, der klinische Befund macht dies erforderlich. Das Stillen sollte während der Behandlung mit TYSABRI beendet werden. UW: Kopfschmerzen, Erbrechen, Fieber, Abgeschlagenheit, Gelenkschmerzen, Harnwegsinfektionen, Nasopharyngitis, Urtikaria. Infusionsbedingte Reaktionen wie Schwindel, Übelkeit, Urtikaria, Rigor, Schüttelfrost, Flushing und Überempfindlichkeitsreaktionen (Siehe V). Infektionen einschliesslich PML und oppor-tunistische Infektionen. Antikörperbildung. Selten: Leberschädigung, erhöhte Leberenzyme. IA: Siehe unter KI. Liste B. Die vollständige Fachinformation ist unter www.swissmedicinfo.ch publiziert. Biogen Idec Switzerland AG, CH-6300 Zug. Stand der Information: August 2011.

Jetzt…

hoch- Wirksam1

BeI MS

… für Morgen

BIOG150 Inserat TYS_148x210+3mm_D_V01.indd 1 22.03.13 14:23

Welcom

e

5

Welcome from the president of the scientific committee

Dear colleagues

On behalf of the national and the executive committee, it is with great pleasure that we invite you to the 2nd Conference of the International MS Cognition Society (IMSCOGS) which will take place from June 28 to 29, 2013 at the University Hospital in Zurich, Switzerland. The upcoming event in Zurich will offer an excellent platform for discussing a topic which is highly relevant for patients’ quality of life and which is still underestimated by treating physicians. The International MS Cognition Society aims to bring together researchers and clinicians around the world who are engaged in the care of MS patients with a specific focus on cognition and other closely related symptoms such as fatigue, depression and anxiety. No effort was spared in order to organize an attractive and diverse program which undoubtedly will foster interesting debates and discussions. We are looking forward to welcoming you in Zurich in June 2013!

PD Iris-Katharina Penner, PhD

President of the committeeBasel, Switzerland

6

Gene

ral

General information

Date

Venue

Website

President IMSCOGS

Scientific committee

Congress secretariat

Friday, June 28 until Saturday, June 29, 2013

Universtity Hospital ZurichGrosser Hörsaal OST BGloriastrasse 29CH - 8091 ZürichWeb: www.usz.ch

www.imk.ch/imscogs2013

Prof. Bruno Brochet, MD; Bordeaux, F

National committee SwitzerlandPD Iris-Katharina Penner, PhD; Basel | Congress PresidentClaudio Gobbi, MD; LuganoProf. Ludwig Kappos, MD; BaselProf. Jürg Kesselring, MD; ValensPD Michael Linnebank, MD; ZurichProf. Roland Martin, MD; ZurichProf. Heinrich Mattle, MD; BernProf. Klaus Opwis, PhD; BaselProf. Renaud Du Pasquier, MD; Lausanne

Executive committeeProf. Maria Pia Amato, MD; Florence, I Prof. Bruno Brochet, MD; Bordeaux, F | President of the societyProf. Ralph Benedict, PhD; Buffalo, US Prof. John DeLuca, MD; West-Orange, US Prof. Sten Fredrikson, MD; Stockholm, SE Païvi Hämäläinen, PhD; Masku, FINProf. Hans-Peter Hartung, MD; Düsseldorf, D Prof. Lauren Krupp, MD; New York, US Prof. Dawn Langdon, PhD; London, UK Prof. Xavier Montalban, MD; Barcelona, E Prof. Alan Thompson, MD; London, UK

IMK Institute for medicine and communication LtdMünsterberg 1, CH-4001 BaselPhone: +41 61 271 35 51, Fax: +41 61 271 33 38E-mail: congress@imk.chwww.imk.ch

7

General

General information General information

Opening hoursCongress secretariat

Opening hoursindustrial exhibition

Credits

Registration

Congress fees

Cancellation fees

Confirmation ofparticipation

Friday, June 28, 2013 08:00-17:30 hSaturday, June 29, 2013 08:00-15:00 h

Friday, June 28, 2013 08:30-17:30 hSaturday, June 29, 2013 08:30-15:00 h

We applied for credits from following society:Swiss Neurological Society

Online via www.imk.ch/imscogs2013for your participation at the congress, your accomodation in Zurichand the social evening.

Registration fees include participation to scientific meetings, entrance to the exhibition, meeting materials, coffee & lunch breaks.On site registrations are possible at the IMK congress secretariat. Fol-lowing credit cards are accepted onsite: Mastercard, Visa, Visa Electron, EC, PostFinance and American Express.

IMK must be informed about cancellations in written form until May 31, 2013. We will be able to reimburse 50% of the congress fees. After May 31, 2013 no refunds will be made.

You will receive a confirmation of participation at the congress secretariat.

Early bird until May 31, 2013

Regular from June 1, 2013

Social evening

Physicians CHF 190.- CHF 240.- CHF 100.-

Assistant/Nurses/Student

CHF 130.- CHF 180.- CHF 60.-

8

Gene

ral

Technical information

The meeting room is equiped with a beamer and laptop. We kindly ask you to bring your presentation on a USB Stick or CD to the meeting room at the latest one hour prior to your session. Presentations with your own laptop are possible.

The official congress language is English.

Please consult the final program for the exact time of your presentation. Within the Free Communications-Session you will have 15 minutes for your presentation (12 minutes presentation, 3 minutes discussion). The authors are requested to prepare a power point presentation.

Posterboards in the format 100cm x 175cm (wide x height) will be at your disposal. Hang-up of the posters: Friday, June 28, 2013 from 08:00 h in the poster exhibition.

Friday, June 28, 2013, 13:30-15:00 h. The authors are requested to present their posters during this time.

The abstracts will be published in the journal „Multiple Sclerosis“.

Presentation

Language Free Communications

Poster exhibition

Posterviewing

Publication

9

General

Technical information

For participants we offer rooms in different hotels. Please consult our website www.imk.ch/imscogs2013 to book your accommodation. Please find below a selection of hotels, further hotels will follow on our website.

Accommodation

Clardige Hotel Zurich

Steinwiesstrasse 8-10 | 8032 Zurich-city center

The Claridge Zurich boutique hotel offers awell-tended environment with furniture ofhigh quality materials. In combination withthe antique design it is perfect for peoplelooking for something special.

Single room for single use from CHF 260.-Double room for double use from CHF 313.-

Sorell Hotel Zürichberg

Orellistrasse 21 | 8044 Zurich

The Sorell Hotel Zürichberg is a unique designhotel high above the city of Zurich. Enjoy the calmand relaxing atmosphere of the hotel, with itsnatural environment far away from the hustle andbustle of the city. You will be inspired by thefantastic views of Zurich, Lake Zurich and the Alps.

Double room for single use from CHF 250.-

Hotel Basilea

Zähringerstrasse 25 | 8001 Zurich

The modern Hotel Basilea is located just a5 minute walk away from Zurich’s main railwaystation, right in the heart of the historic old town.The rooms are modern and functional and offerfree Wi-Fi connections.

Single room for single use from CHF 165.-Double room for double use from CHF 235.-

10

Gene

ral

Flights to Zurich with SWISS

As official carrier to this conference Swiss International Air Lines offers you the best booking flexibility together with Swiss product and service quality, all at a significantly discounted price. As the national airline of Switzerland we offer event participants a reduction of up to 15% off regular fares. Your stay in Switzerland begins the moment you board one of our aircraft. Special congress fares are indicated with a "C" and make it possible for you to rebook flexibly or cancel if necessary. Reductions depend on the fare type, routing and availability and are valid on the full SWISS network for flights to Switzerland, including flights operated by one of our partner airlines with an LX flight number. These fares are bookable with immediate effect for the travel period 14 days before and after the event.To take advantage of this offer, book simply and conveniently on swiss.com via the link "www.swiss.com/event". The necessary event code is: 2517-2059-4854-7868.

Zurich is located at the heart of Europe and the center of Switzerland, making it easily accessible from all directions – whether you travel by train, car, or plane. The international Zurich Airport is situated in close proximity to Zurich and is considered one of the world’s best airports. Transfers Zurich Airport - Zurich City

TaxiThe journey from the airport to the city center is just around 20 minutes by taxi. The taxi ranks are located directly by the exits at the Arrival terminals 1 and 2. The trip by taxi from the airport to the center of Zürich costs around CHF 50 (EUR 35).

Hotel Shuttle BusThe city hotel shuttle bus CHECK-IN all-ways offers services every 30 minutes (6:30am - 2pm and 5pm - 11pm) or every 60 minutes (2pm - 5pm) from Zurich Airport to Zurich City. Furthermore many hotels near to the airport and in the city offer their own courtesy bus service. These buses depart from the area in front of the Arrival terminals 1 and 2.

TrainThe railway station at the Zurich Airport is located directly beneath the Airport Shopping area, just minutes away from Check-Ins 1-3 as well as Arrival Halls 1 and 2. Trains run every 10 minutes to and from the Zurich Main Station during peak traffic times (travel time 10 minutes).Online Timetable: www.sbb.ch

Travel information

11

General

Directions in Zurich Coming from Zurich Main Railway Station, tramways Nr. 6 (direction "Zoo") and Nr. 10 (direction "Zurich Airport") will bring you to the tram stop "ETH / Universitätsspital", which is right in front of the main entrance of the University Hospital Zurich. However, in order to get to the Grosser Hörsaal OST B, the best way to enter the building is by using the entrance at Gloriastrasse 29 (on the left side of the building). The nearest tramstop to this entrance is called "Platte" and can be reached with tramway Nr. 6 from Zurich Main Station.

A detailled plan of the University Hospital Zurich may be found on the congress website:www.imk.ch/imscogs2013 in the heading «Travel information».

Travel information

12

Gene

ral

Social program

Speakers dinner

Social evening

Address

Costs

The speakers dinner will be held on Thursday, June 27, 2013 at the restaurant “Oberer Mönchhof“.Only for invited guests.

The social evening will take place on Friday, June 28 2013 at the „Hotel Zürichberg“. The restaurant perfectly combines the secret of creative and contemporary culinary art, elegance in a relaxed atmosphere and a fantastic view of Lake Zurich and the city of Zurich. Hotel ZürichbergOrellistrasse 21CH-8044 Zürichwww.zuerichberg.ch

Costs for physicians: CHF 100.-Costs for students, assistants and nurses: CHF 60.-

13

General

Social program Partner companies

We would like to thank the following companies for supporting the 2nd Conference ofthe International MS Cognition Society as a sponsor (updated in May 2013):

Premium Partner 2013

Partner 2013

Frid

ay

14

Daily overview Friday | 28.06.2013

Plenary Room Poster exhibition Industrial exhibition

09:00 - 09:15 Welcome

09:15 - 09:30 Neuroinflammationand

Neurodegeneration09:30 - 09:45

09:45 - 10:45 Free Communications

10:45 - 11:15 Coffee break

11:15 - 11:30 BICAMS,update

on validation11:30 - 11:45

11:45 - 12:30 Free Communications

12:30 - 13:30 Lunch

13:30 - 15:00 Guided Poster session

15:00 - 15:30 Coffee break

15:30 - 15:45 Utility of neuro-psychological testing in

children with MS15:45 - 16:00

16:00 - 16:45 Free Communications

16:45 - 17:30 Welcome reception

from 19:00 Social dinner

Main sessions Abstracts General informations Breaks

15

16

16

16

16

17

15

15

Friday

15

Friday | 28.06.2013

09:00-09:15

09:15-10:45

09:15-09:45

09:45-10:45

09:45-10:00

10:00-10:15

10:15-10:30

10:30-10:45

10:45-11:15

Welcome by the congress presidentPD Iris-Katharina Penner, PhD; Basel, CH Session IChairs: Prof. Bruno Brochet, MD; Bordeaux, F &Prof. Roland Martin, MD; Zurich, CH

Neuroinflammation and Neurodegeneration in relation to cognitionProf. Jeroen Geurts, PhD; Amsterdam, NL

unrestricted grant

Free communications

Callosal atrophy in multiple sclerosis is related to cognitive speedG. Bergendal, J. Martola, L. Stawiarz, M. Kristoffersen-Wiberg,S. Fredrikson, O. Almkvist; Stockholm, SE

It is all about speed: information processing speed and white matter integrity changes in MSJ. Burggraaff, H.H. Hulst, J.J.G. Geurts, M.M. Schoonheim, F. Barkhof, B.M.J. Uitdehaag, Ch. Polman; Amsterdam, NL

The impact of cortical thinning on executive dysfunction in MS patientsO. Geisseler, T. Pflugshaupt, L. Bezzola, K. Reuter, P. Brugger,B. Schuknecht, M. Linnebank; Zurich, CH, Lucerne, CH

The relationship between cognitive impairment and APOE genotype in a multiple sclerosis cohortP. Ioannidis, E. Aretouli, E. Konstantinopoulou, R. Lagoudaki, N. Grigoriadis, D. Karacostas; Thessaloniki, GR

Coffee break

Frid

ay

16

Friday | 28.06.2013

11:15-12:30

11:15-11:45

11:45-12:30

11:45-12:00

12:00-12:15

12:15-12:30

12:30-13:30

13:30-15:00

15:00-15:30

15:30-16:45

15:30-16:00

Session IIChairs: Prof. Xavier Montalban, MD; Barcelona,E &Prof. John DeLuca, MD; West-Orange, USA

BICAMS Update on validationProf. Ralph Benedict, PhD; Buffalo, USA

Free communications

Does the Brief International Cognitive Assessment for MS (BICAMS) catch the cognitive problems of a sample of well-educated recently diagnosed MS patients in Oslo?G.O. Nygaard, H.F. Harbo, E.G. Celius, N.I. Landrø; Oslo, NO

Reliable change indices for the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)S.Ó Donnchadha, T. Burke, J. Bramham, M.C. O’Brien, R. Reilly, H. Kiiski, R. Whelan, R. Lonergan, K. Kinsella, O. Kenny, S. Kelly, C. McGuigan, M. Hutchinson, N. Tubridy; Dublin, IR; Burlington; US

Parametric assessment of information processing capacity at different stages of Multiple Sclerosis (MS)P. Bublak, M. Schwab, R. Deppe, J. Faiss, M. Fischer, F. Hoffmann, A. Kunkel,P. Redel, E. Stadler,M. Sailer, K. Voigt, U.K. Zettl, W. Köhler; Jena, DE;Halle, DE; Teupitz, DE; Wermsdorf, DE; München, DE; Magdeburg, DE;Rostock, DE

Lunch

Guided Postersession in room “Kurszimmer OSTB“Chairs: PD Iris-Katharina Penner, PhD; BaselClaudio Gobbi, MD; LuganoPD Michael Linnebank, MD; Zurich

Coffee break

Session IIIChairs: Prof. Dawn Langdon, PhD; London, UK &Prof. Ralph Benedict, PhD; Buffalo, US

Utility of neuropsychological testing in children with MS Prof. Maria Pia Amato, MD; Florence, IT

Friday

17

Friday | 28.06.2013 Friday | 28.06.2013

16:00-16:45

16:00-16:15

16:15-16:30

16:30-16:45

16:45-17:30

From 19:00

Free communications

Longitudinal Evaluation of Cognitive Impairment in Pediatric MSL. Charvet, D. Serafin, K. Vazquez, J. Ackerson, E. Braaten, T. Brown, E. O’Donnell, J. Parrish, T. Preston, M. Zaccariello, A. Belman, C. Casper, T. Chitnis, M. Gorman, L. Julian, J. Ness, M. Patterson, M. Rodriguez, E. Waubant, B. Weinstock-Guttman, A. Yeh, R. Benedict, L. Krupp; Stony Brook, US; Tuscaloosa, US; Buffalo, US; Boston, US; Rochester, US; Salt Lake City, US; San Francisco, US; Toronto, CAHow accurate are self-reports of executive functioning in

Multiple Sclerosis?K. van der Hiele, N.G.A Kamminga, R.P. Ruimschotel, H.A.M. Middelkoop, L.H. Visser; Leiden, NL; Maassluis, NL; Rotterdam, NL; Tilburg, NL

6 years follow-up of attentional and cognitive functions in early relapsing-remitting multiple sclerosis (RRMS) patientsH. Schreiber, M. Lang, A. Fuchs, C. Kauderer, T. Fischer, M. Freidel, W. Hofmann, W. Elias, G. Reifschneider, S. Ries, B. Bühler, I. Uttner,S. Schlegel, C. Ring, I.K. Penner, A. Bergmann; Ulm, DE; Mutlangen, DE; Günzburg, DE; Offenbach, DE; Kaltenkirchen, DE; Aschaffenburg, DE; Hamburg, DE; Erbach, DE; Mannheim, DE; Ulm, DE; Neuburg, DE; Basel, CH

Welcome reception

Social evening at the Restaurant Zürichberg

Hotel ZürichbergOrellistrasse 21CH-8044 Zürichwww.zuerichberg.ch

Satu

rday

18

Daily overview Saturday | 29.06.2013

Plenary Room Poster exhibition Industrial exhibition

09:00 - 09:15 Optical coherence tomography-first data on

cognition09:15 - 09:30

09:30 - 10:45 Free Communications

10:45 - 11:15 Coffee break

11:15 - 11:30 Effects of non-pharmacological

approaches on cognitive functions11:30 - 11:45

11:45 - 12:30 Free Communications

12:30 - 13:30 Lunch

13:30 - 13:45 Effects of pharmacotherapy on cognitive functions13:45 - 14:00

14:00 - 14:30 Free Communications

14:30 - 15:30 Discussion

15:30 - 16:15 General AssemblyIMSCOGS

21

21

21

21

19

19

20

20

Main sessions Abstracts General informations Breaks

Saturday

19

Saturday | 29.06.2013

09:00-10:45

09:00-09:30

09:30-10:45

09:30-09:45

09:45-10:00

10:00-10:15

10:15-10:30

10:30-10:45

10:45-11:15

Session IVChairs: Prof. Lauren Krupp, MD; New York, USA &Prof. Maria Pia Amato, MD; Florence, IT

Optical coherence tomography-first data on cognition Prof. Paul Friedemann, MD; Berlin, D

unrestricted grant

Free communications

Prevalence and pattern of cognitive dysfunction in Indian patients with multiple sclerosisP. Agarwal, S. Johri, S.P. Gorthi, Y.S. Sirohi, N. Yaddanapudi; New Dehli, IN; Chandigarh, IN

Is visual function testing influenced by cognitive performance in multiple sclerosis?L. Wieder, L.M. Pech, G. Gäde, H. Zimmermann, J. Bellmann-Strobl, F. Paul, A.U. Brandt; Berlin, DE

Neuroimaging and Cognition using Near Infrared Spectroscopy in Multiple SclerosisJ. Stojanovic, G. Wylie, G.T. Voelbel, J. DeLuca; West Orange, US

Correlation of cerebral magnetic resonance elastography with cognitive performance in patients with multiple sclerosisE. Wuerfel, A. Brandt, K. Schregel, F. Paul, I. Sack, J. Wuerfel; Goettingen, DE; Berlin, DE; Luebeck, DE

Detection of cognitive impairment in MS based onan EEG P300 paradigmJ. Van Schependom, M.B. D’hooghe, M. D’hooge, K. Cleynhens, J. De Keyser, G. Nagels; Brussel, BE; Melsbroek, BE

Coffee break

Satu

rday

20

Saturday | 29.06.2013

Session VChairs: Prof. Sten Fredrikson, MD; Stockholm,SE & Prof. Herbert Schreiber, MD; Ulm, D

Effects of non-pharmacological approaches on cognitive functionsProf. John DeLuca, MD; West-Orange, USA

Free communications

Case-based approach to evaluate the efficacy of working memory training in juvenile Multiple SclerosisM. Hubacher, P. Weber, M. Stoecklin, K. Specht, L. Kappos, K. Opwis, I.K. Penner; Basel, CH; Bergen,

Long-term effects of cognitive rehabilitation in multiple sclerosis: 12-month follow-upB. Topcular, D. Yandim-Kuscu, I. Guclu, A. Altinkaya, D Kirbas,G Akman-Demir; Istanbul, TR

Personalized on-line (computer-based) cognitive training (CogniFit) for patients with MSA. Miller, E. Shatil; Haifa, IR; Yoqneam Ilit, IR

Lunch

11:15-12:30

11:15-11:45

11:45-12:30

11:45-12:00

12:00-12:15

12:15-12:30

12:30-13:30

Saturday

21

Saturday | 29.06.2013 Saturday | 29.06.2013

Session VIChairs: Prof. Alan Thompson, MD; London, UK &PD Iris-Katharina, PhD; Basel, CH

Effects of pharmacotherapy on cognitive functionsProf. Ludwig Kappos, MD; Basel, CH

Free communications

Impact of Natalizumab treatment on attention, mood and fatigue in relapsing-remitting MSA. Kunkel, J.H. Faiss, W. Köhler, M. Fischer; Teupitz, DE; Wermsdorf, DE

Repetitive transcranial magnetic stimulation improves working memory and induces changes in brain activity of Multiple Sclerosis patientsT. Goldschmidt, H.E. Hulst, S. De Wit, Y.D. van der Werf, O.A. van den Heuvel, F. Barkhof, C. Polman, M.A. Nitsche, J.J.G. Geurts; Amsterdam, NL; Goettingen, DE

Discussion and closing remarks

General assembly IMSCOGS

13:30-14:30

13:30-14:00

14:00-14:30

14:00-14:15

14:15-14:30

14:30-15:30

15:30-16:15

Promoting partners and partnership in hea lthcare

Institute for medicine and communication Ltd | Münsterberg 1 CH-4001 Basel | Phone +41 61 271 35 51 | Fax +41 61 271 33 38 | mail@imk.ch

Conference organizationAdministrative managementCommunications

IMIMWM Inserat A5_15.indd 1 23.05.13 14:13

Addresses

23

Adresses of invited speakers and committee

Page Page

6,1619

6,1617

6,15

6,1619,20

6,2025

19

AProf. Maria Pia Amato, MDUniversity of FlorenceDepartment of NeurologyViale Morgagni 85IT-50134, Florence

BProf. Ralph Benedict, PhDSUNY Buffalo School of Medicine100 High StreetUS-NY 14203 Buffalo

Prof. Bruno Brochet, MDUniversité Bordeaux-SegalenService de NeurologieF-33076 Bordeaux

DProf. John DeLuca, MDKessler Foundation1199 Pleasant Valley WayUS-NJ 07052 West Orange

FProf. Sten Fredrikson, MDKarolinska InstitutetR54, Karolinska University Hospital HuddingeSE-14186 Stockholm

Prof. Paul Friedemann, MDNeuroCure Clinical Research CenterCharitéplatzD-10117 Berlin

GProf. Jeroen Geurts, MDVrije University Medical CenterDepartment of Anatomy andNeurosciencesVan der Boechorststraat 7NL-1081 BT Amsterdamt

Claudio Gobbi, MDOspedale Civico, NeurologiaVia Tesserete 46CH-6900 Lugano

HProf. Hans-Peter Hartung, MDNeurologische KlinikHeinrich-Heine UniversitätMoorenstrasse 5D-40225 Düsseldorf

KProf. Ludwig Kappos, MDUniversity Hospital BaselNeurologyPetersgraben 4CH-4031 Basel

Prof. Jürg Kesselring, MDKlink Valens, Neurologieund NeurorehabilitationCH-7317 Valens

Prof. Lauren Krupp, MDStony Brook University Medical Center179 N Belle Mead RdUS-NY 11794-8121 New York

15,21

6

6

6,2021

6

6,1719

Addr

esse

s

24

Adresses of invited speakers and committee

Page Page

6,16

6,15

6,15

6

6,16

6,20

LProf. Dawn Langdon, PhDRoyal Holloway University of LondonEgham HillUK-Egham Surrey TW20 0EX London

PD Michael Linnebank, MDUniversitätsSpital ZürichKlinik für NeurologieFrauenklinikstasse 26CH-8091 Zurich

MProf. Roland Martin, MDUniversitätsSpital ZürichKlinik für NeurologieCH-8091 Zurich

Prof. Heinrich Mattle, MDInselspital BernNeurologisch-neurochirurgischePoliklinikCH-3010 Bern

Prof. Xavier Montalban, MD, PhDUnitat de Ressonància MagnèticaHospital Vall d’HebronPasseig Vall d’Hebron 119-129ES-08035 Barcelona

OProf. Klaus Opwis, PhDUniversität BaselInstitut für PsychologieCH-4055 Basel

PProf. Renaud Du Pasquier, MDCHUVNeurologie BH-1046, rue du BugnonCH-1011 Lausanne

PD Iris-Katharina Penner, PhDUniversity of BaselDepartment of Cognitive PsychologyMissionsstrasse 60/62CH-4055 Basel

SProf. Herbert Schreiber, MDNeurologische Praxisgemeinschaft UlmPfauengasse 8D-89073 Ulm

TProf. Alan Thompson, MDUCL Institute of NeurologyDepartment of Brain Repairand Rehabilitation8-11 Queen SquareUK-WC1N 3B London

6

6,1517

17,20

6,21

25

Posters

Posters

A lexical access deficit in Clinical Isolated Syndrome: correlation with brain MRI parametersH. Joly, M. Cohen, C. Lebrun; Nice (FR)

A possible influence of fatigue in the risk of work accidents in a sample of MS patientsC. Incerti, O. Argento, G. Magistrale, C. Caltagirone, G. Di Battista, E. Ferraro, U. Nocentini, V. Pisani; Rome (IT)

BRBN-T validation: Adapting the SRT and WLG tests to the Portuguese populationM. R. Neves, A.M. Passos, A. Ferreira, C. Sousa, M.J. Sá; Lisboa (PT), Porto (PT)

Cerebellum and cognition in multiple sclerosisB. Brochet, I. Lacoste, J. Charré-Morin, M. Deloire; Bordeaux (FR)

Cognitive changes during and after MS relapses - 6 months follow-upL. Vahter, L. Bachmann, T. Saarup, K. Rohulaid, K. Kannel, A. Reitsnik, U. Sorro, K. Gross-Paju; Tallinn (EE)

Cognitive Dysfunction Predicts Negative Work Events and Accommodations in Multiple SclerosisN.A. Emmert, J.D. Rodgers, R. Kininger, B. Weinstock-Guttman, R.H.B. Benedict; Buffalo (US)

Cognitive function in Turkish patients with relapsing remitting multiple sclerosisZ. Gedik, E. Idiman, S. Ozakbas; Izmir (TR)

Cognitive functioning in Multiple Sclerosis: the relationship with radial diffusivityR. Magalhães, L. Gomes, J. Alves, L. Maia, F. Palavra, J.G. Gonçalves, O.F. Gonçalves, A. Sampaio; Brage (PT), Coimbra (PT)

Computer-based assessment of memory and selective attention in MS patientsG. Adler, M. Bektas, N. Baumgart, Y. Lembach; Mannheim (DE)

Correlations between auditory consonant trigram test, paced auditory serial addition test health-related quality of life during and after treatment of relapses in patients with clinically isolated syndromeOzakbas, Piri Cinar, Ozturk, Gurkan, Idiman; Izmir (TR)

P01

P02

P03

P04

P05

P06

P07

P08

P09

P10

26

Post

ers

Posters

Diffustion tensor imaging and cognitive impairment in early relapsing-remitting multiple sclerosisS. Planel, R. Anxionnat, M. Debouverie, C. Latarche, G. Hossu, E. Micard, E. Morele, L. Rivail-Eloy, G. Lesanne, M. Domingo, A.L. Derelle, C. Barbier, E. Schmitt, M. Braun, S. Bracard;

Episodic short-term memory deficits in MS subtypesG. Adler, M. Bektas, N. Baumgart, Y. Lembach; Mannheim (DE)

Fatigue as the best predictor variable of self-rated disability in a sample of MS patientsG. Magistrale, R. Medori, D. Cadavid, O. Argento, C. Incerti, V. Pisani, C. Caltagirone, U. Nocentini; Rome (IT), Cambridge (US)

Fatigue is associated with radial diffusivity in patients with early stages of Multiple SclerosisL.R. Gomes, R. Magalhães, M. Parreira, L. Maia F. Palavra, G. Gonçalves, A. Sampaio, J.J. Cerqueira, O.F. Gonçalves; Braga (PT), Coimbra (PT)

fMRI during PASAT and PVSAT in healthy volunteers and patients with mild and moderate multiple sclerosisJ. Gielen, J. Van Schependom, W. Van Hecke, P. M. Parizel, G Nagels; Brussel (BE), Leuven (BE)

Impact of depression and fatigue on cognitive functions in multiple sclerosisV. Ignatova, Ts. Stoyanova, L. Todorova, L. Haralanov; Sofia (BG

Interest of moral/conventional judgment task in multiple sclerosis (MS) patientsN. Ehrle, A. Potet, A. Hody, M.P. Chaunu, A. Tourbah, S. Bakchine; Reims (FR)

Is the decrease of the qualitative performance at the end of attentional tests due to fatigue in multiple sclerosis patients?N. Moyano, G. Delrue, S. Genon, E. Jimenez, L. Denis, E. Hody, S. Adam, D. Guillaume; Fraiture-en-Condroz (BE), Liège (BE)

Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigabilityM. Neumann, D. Claros-Salinas, R. Gütler R. Ulrich, A. Sterr, C. Dettmers; Konstanz (DE), Tübingen (DE), Surrey (UK)

P11

P12

P13

P14

P15

P16

P17

P18

P19

27

Posters

Posters

Normative data for two parallel Italian Versions of CVLT-IIO. Argento, P. Vanzo, V. Pisani, G. Magistrale, C. Caltagirone, U. Nocentini; Rome (IT)

One-year cognitive follow-up of patients with clinically isolated syndromeM. López-Góngora, A. Martínez-Domeno, A. Escartin-Siquier; Barcelona (ES)

Pattern of cognitive impairment and related factors in clinically isolated syndromeOzakbas, Piri Cinar, Gurkan, Ozturk, Idiman; Izmir (TR)

Pupillometry indicates increased cognitive effort in response to easy cognitive taks in newly diagnosed MS patientsS.A. de Rodez Benavent, G.O. Nygaard, S. Tønnesen, E.G. Celius, N.I. Landrø, B. Laeng; Oslo (NO)

Social cognition in multiple sclerosis patientsC. Dulau, H. Diaz, A. Prouteau, M. Deloire, J. Charré-Morin, A. Saubusse, B. Brochet; Bordeaux (FR)

Spasticity perception in MS is not influenced by other concomitant symptoms like sleep, fatigue, and emotional or cognitive disordersA. Gil, C. González, S. Peralta, B. Guiu, M. Gil, E. Lacasa, L. Brieva; Lleida (ES)

The recently unemployed: Who are they and what is their disease, cognitive, and psychological profile?L.B. Strober, N. Chiaravalloti, J. DeLuca; West Orange (US)

Theory of Mind deficits in patients with Multiple Sclerosis – A separate entity of socio-cognitive impairment?D. Zwahlen, S. Schaub, Ö. Yaldizli, K. Opwis, J.M. Annoni, L. Kappos, I.K. Penner; Basel (CH), Fribourg (CH)

Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): UK normative dataA.J. Orchard, G. Giavanoni, D.W. Langdon; London (UK)

P20

P21

P22

P23

P24

P25

P26

P27

P28

Your partner in rare diseasesand multiple sclerosis

Fighting complex diseases with groundbreaking therapies.

Visit www.genzyme.com

genzyme_anzeige_A5_2012-08-13_v03_kh.indd 1 17.08.12 14:12